Basic principles of neuromuscular transmission

• Published in: Anaesthesia Vol. 64; no. s1; pp. 1 - 9
• Main Authors: Martyn, J. A. J., Fagerlund, M. Jonsson, Eriksson, L. I.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.03.2009
• Subjects: Anesthesia; Anesthesiology; Humans; Medicin och hälsovetenskap; Musculoskeletal system; Neuromuscular Blocking Agents - antagonists & inhibitors; Neuromuscular Blocking Agents - pharmacology; Neuromuscular Junction - drug effects; Neuromuscular Junction - physiology; Neurotransmitters; Physiology; Receptors, Cholinergic - physiology; Synaptic Transmission - physiology; Synaptic Vesicles - physiology
• ISSN: 0003-2409; 1365-2044; 1365-2044
• DOI: 10.1111/j.1365-2044.2008.05865.x

Summary Neuromuscular transmission at the skeletal muscle occurs when a quantum of acetylcholine from the nerve ending is released and binds to the nicotinic acetylcholine receptors on the postjunctional muscle membrane. The nicotinic acetylcholine receptors on the endplate respond by opening channels for the influx of sodium ions and subsequent endplate depolarisation leads to muscle contraction. The acetylcholine immediately detaches from the receptor and is hydrolysed by acetylcholinesterase enzyme. Suxamethonium is a cholinergic agonist stimulating the muscle nicotinic acetylcholine receptors prior to causing neuromuscular block. Non‐depolarising neuromuscular blocking drugs bind to the nicotinic acetylcholine receptors preventing the binding of acetylcholine. Non‐depolarising neuromuscular blocking drugs also inhibit prejunctional α3β2 nicotinic acetylcholine autoreceptors, which can be seen in the clinical setting as train‐of‐four fade. In some pathological states such as denervation, burns, immobilisation, inflammation and sepsis, there is expression of other subtypes of nicotinic acetylcholine receptors with upregulation of these receptors throughout the muscle membrane. The responses of these receptors to suxamethonium and non‐depolarising neuromuscular blocking drugs are different and explain some of the aberrant responses to neuromuscular blocking drugs.